Vimarsana
Biggest News Aggregation in the World

Mutant Unresectable News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Mutant Unresectable. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Mutant Unresectable Today - Breaking & Trending Today

ENHERTU® (fam-trastuzumab deruxtecan-nxki) improved PFS in HER2-low and ultralow - Vimarsana News

ENHERTU® (fam-trastuzumab deruxtecan-nxki) improved PFS in HER2-low and ultralow

Published: April 29, 2024

ENHERTU demonstrated statistically significant and clinically meaningful improvement in progression-free survival in HR-positive, HER2-low metastatic breast cancer following one or more lines of...

Source: marketscreener.com
Related Topics:
United KingdomIsrael GeneralDaiichi SankyoTrastuzumab DeruxtecanCapecitabine MonotherapyEnd Results ProgramMerck Co IncNational Cancer InstituteDaiichi Sankyo IncLow Metastatic Breast CancerSolid TumorsPositive Locally AdvancedMetastatic Gastric CancerPositive Metastatic BreastLow Metastatic BreastMutant UnresectableMetastatic SolidReproductive PotentialHepatic ImpairmentPrescribing InformationRare DiseasesCancer ResPlus ExemestaneOestrogen ReceptorNegative Advanced Breast
ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial - Vimarsana News

ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial

Published: April 29, 2024

Daiichi Sankyo and AstraZeneca’s ENHERTU also demonstrated a clinically meaningful progression-free survival improvement in patients with HER2 ultralow expression Plans for global regulatory...

Source: marketscreener.com
Related Topics:
Israel GeneralDaiichi SankyoNational Cancer InstituteDaiichi Sankyo IncLow Metastatic Breast CancerSolid TumorsPositive Locally AdvancedMetastatic Gastric CancerAdverse ReactionsPositive Metastatic Breast CancerMutant UnresectableMetastatic Solid TumorsReproductive PotentialHepatic ImpairmentPrescribing InformationCancer ResStat FactsFemale Breast CancerAccessed AprilPathol Transl
ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors - Vimarsana News

ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors

Published: April 6, 2024

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Apr 5, 2024--

Source: valdostadailytimes.com
Related Topics:
United StatesDaiichi SankyoJennifer BrennanDave FredricksonKen KellerAmerican Society Of Clinical OncologyEuropean Society For Medical OncologyMerck Co IncUniversity Of Texas Md Anderson Cancer CenterDaiichi Sankyo Co LtdClinical Development ProgramDrug AdministrationDaiichi Sankyo IncVirtual CongressNational Comprehensive Cancer NetworkReal Time Oncology ReviewPriority ReviewBreakthrough TherapyProject OrbisFunda Meric BernstamInvestigational Cancer TherapeuticsGlobal HeadOncology BusinessExecutive Vice PresidentOncology Business Unit